Clinical Trial

Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective of this study is to determine whether neoadjuvant chemotherapy combined with slulimumab sequential concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced cervical cancer could improve progression-free survival rates. Women in the experimental arm will receive neoadjuvant chemotherapy (cisplatin plus paclitaxel) combined with slulimumab every 21 days during 2 cycles followed by concurrent chemoradiation therapy. Women in the control arm will receive concurrent chemoradiation therapy alone. 286 patients will be recruited during 2 years, with 3 years of follow up period.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-12-28; most recent amendment 2023-12-25.
Status change: Not Yet Recruiting → Recruiting 2023-04-23
Trial Details
NCT Number NCT05173272
Lead Sponsor Sichuan Cancer Hospital and Research Institute
Conditions Cervical Cancer
Enrollment 286 participants
Start Date 2023-07-24
Primary Completion 2027-12-28 (estimated)
Study Completion 2028-12-28 (estimated)
Updated on ClinicalTrials.gov 2023-12-27